These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 30528077)

  • 21. Anatomical distribution of residual cancer in patients with oesophageal squamous cell carcinoma who achieved clinically complete response after neoadjuvant chemoradiotherapy.
    Chao YK; Chuang WY; Yeh CJ; Chang HK; Tseng CK
    Eur J Cardiothorac Surg; 2018 Jan; 53(1):201-208. PubMed ID: 28977486
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neoadjuvant Chemoradiotherapy for Stage II or III Esophageal Squamous Cell Carcinoma.
    Kawai T; Kochi M; Fujii M; Song K; Hagiwara K; Watanabe M; Matsuno Y; Suda H; Yagi R; Takayama T
    Anticancer Res; 2017 Jun; 37(6):3301-3306. PubMed ID: 28551681
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The patterns and risk factors for relapse in oesophageal squamous cell cancers that achieve pathological complete response to neoadjuvant chemoradiotherapy.
    Zhong J; Fang S; Chen R; Yuan J; Xie X; Lin T; Liu M; Liu Q; Fu J
    Eur J Cardiothorac Surg; 2024 Jun; 65(6):. PubMed ID: 38810125
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of neoadjuvant treatment in clinical T2N0M0 oesophageal cancer: results from a retrospective multi-center European study.
    Markar SR; Gronnier C; Pasquer A; Duhamel A; Beal H; Théreaux J; Gagnière J; Lebreton G; Brigand C; Meunier B; Collet D; Mariette C;
    Eur J Cancer; 2016 Mar; 56():59-68. PubMed ID: 26808298
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical Implications of Conversion Surgery After Induction Therapy for T4b Thoracic Esophageal Squamous Cell Carcinoma.
    Miyata H; Sugimura K; Motoori M; Omori T; Yamamoto K; Yanagimoto Y; Shinno N; Yasui M; Takahashi H; Wada H; Ohue M; Yano M
    Ann Surg Oncol; 2019 Dec; 26(13):4737-4743. PubMed ID: 31414291
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The current optimal multimodality treatments for oesophageal squamous-cell carcinoma: A systematic review and meta-analysis.
    Li F; Ding N; Zhao Y; Yuan L; Mao Y
    Int J Surg; 2018 Dec; 60():88-100. PubMed ID: 30389537
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Esophagectomy versus definitive chemoradiotherapy for patients with clinical stage N0 and pathological stage T1b esophageal squamous cell carcinoma after endoscopic submucosal dissection: study protocol for a multicenter randomized controlled trial (Ad-ESD Trial).
    Yang Y; Su Y; Zhang X; Liu J; Zhang H; Li B; Hua R; Tan L; Chen H; Li Z
    Trials; 2020 Jul; 21(1):603. PubMed ID: 32611448
    [TBL] [Abstract][Full Text] [Related]  

  • 28. What is the optimal interval between chemoradiation and esophagectomy?
    Martin LW
    Semin Thorac Cardiovasc Surg; 2012; 24(2):87-9. PubMed ID: 22920522
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The impact of adjuvant therapies on patient survival and the recurrence patterns for resected stage IIa-IVa lower thoracic oesophageal squamous cell carcinoma.
    Wang Y; Zhu L; Xia W; Wu L; Wang F
    World J Surg Oncol; 2018 Nov; 16(1):216. PubMed ID: 30404621
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Time interval between neoadjuvant chemoradiotherapy and surgery for oesophageal or junctional cancer: A nationwide study.
    van der Werf LR; Dikken JL; van der Willik EM; van Berge Henegouwen MI; Nieuwenhuijzen GAP; Wijnhoven BPL;
    Eur J Cancer; 2018 Mar; 91():76-85. PubMed ID: 29353163
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Higher Doses of Neoadjuvant Radiation for Esophageal Cancer Do Not Affect the Pathologic Complete Response Rate or Survival: A Propensity-Matched Analysis.
    Worrell SG; Towe CW; A Dorth J; Machtay M; Perry Y; Linden PA
    Ann Surg Oncol; 2020 Feb; 27(2):500-508. PubMed ID: 31571054
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neoadjuvant vs definitive concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma patients.
    Chen CY; Li CC; Chien CR
    World J Surg Oncol; 2018 Jul; 16(1):141. PubMed ID: 30007409
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Impact of Pretreatment PET/CT Nodal Status on Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemoradiation.
    Chen JX; Lu TY; Fang HY; Lin YS; Lee JM
    World J Surg; 2020 Jul; 44(7):2323-2331. PubMed ID: 32296872
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nomograms to predict survival rates for esophageal cancer patients with malignant behaviors based on ICD-0-3.
    Sun Y; Wang J; Li Y; Pan S; Yang T; Sun X; Wang Y; Shi X; Zhao X; Zhang X
    Future Oncol; 2019 Jan; 15(2):121-132. PubMed ID: 30232909
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sex differences in the prognosis after surgery for esophageal squamous cell carcinoma and adenocarcinoma.
    Kauppila JH; Wahlin K; Lagergren P; Lagergren J
    Int J Cancer; 2019 Mar; 144(6):1284-1291. PubMed ID: 30168595
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current status of and perspectives regarding neoadjuvant chemoradiotherapy for locally advanced esophageal squamous cell carcinoma.
    Saeki H; Nakashima Y; Zaitsu Y; Tsuda Y; Kasagi Y; Ando K; Imamura Y; Ohgaki K; Ito S; Kimura Y; Egashira A; Oki E; Morita M; Maehara Y
    Surg Today; 2016 Mar; 46(3):261-7. PubMed ID: 25740123
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current Advancement in Multidisciplinary Treatment for Resectable cStage II/III Esophageal Squamous Cell Carcinoma in Japan.
    Matsuda S; Takeuchi H; Kawakubo H; Ando N; Kitagawa Y
    Ann Thorac Cardiovasc Surg; 2016 Oct; 22(5):275-283. PubMed ID: 27384595
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcomes of Radiation-Associated Esophageal Squamous Cell Carcinoma: The MSKCC Experience.
    Nobel TB; Barbetta A; Hsu M; Tan KS; Pinchinat T; Schlottmann F; Bains MS; Ku GY; Wu AJ; Patti MG; Jones DR; Molena D
    J Gastrointest Surg; 2019 Jan; 23(1):11-22. PubMed ID: 30215197
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and Safety of Neoadjuvant Chemoradiotherapy Following Esophagectomy with Japanese-style Extended 3-Field Lymphadenectomy for Thoracic Esophageal Cancer.
    Motoyama S; Sato Y; Sasaki T; Wakita A; Kawakita Y; Liu J; Nagaki Y; Saito H; Imai K; Konno H; Mizusawa KT; Minamiya Y
    Anticancer Res; 2017 Oct; 37(10):5837-5843. PubMed ID: 28982909
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative effectiveness of upfront esophagectomy versus induction chemoradiation in clinical stage T2N0 esophageal cancer: A decision analysis.
    Semenkovich TR; Panni RZ; Hudson JL; Thomas T; Elmore LC; Chang SH; Meyers BF; Kozower BD; Puri V
    J Thorac Cardiovasc Surg; 2018 May; 155(5):2221-2230.e1. PubMed ID: 29428700
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.